Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Keros Therapeutics, Inc.

NASDAQ: KROS · Life Sciences · 6 alerts · CIK 1664710

Share price
$10.03Close, Nov 16
Market cap
$197M
Shares outstanding
19.62MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Keros Therapeutics, Inc. filings on SEC EDGAR ↗

8:01 AM ET 8-K
Licensing Deal

Keros Therapeutics Licensing Deal with Takeda Pharmaceuticals U.S.A., Inc. Worth $20M

Keros Therapeutics announced it will receive a $20 million development milestone payment from its partner Takeda following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept. The payment is part of a global license agreement that includes potential milestones exceeding $1.1 billion. Keros intends to distribute 25% of the net cash proceeds from this milestone to its stockholders.

Value
$20M
Counterparty
Takeda Pharmaceuticals U.S.A., Inc.
8:02 AM ET 8-K
Clinical Trial Data

Keros Therapeutics Clinical Trial Data

Keros Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial evaluating rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). The open-label, multi-cohort trial will assess safety, tolerability, and functional improvements in ambulatory and non-ambulatory patients, with initial data expected in the first half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.